Most Read

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, which is administered by subcutaneous injection in combination with intravenous (IV) chemotherapy. Phesgo is said

Theravance is considering that the TD-0903 can block the cytokine storm linked with ALI and prevent progression to acute respiratory distress syndrome (ARDS). According to the company, the

RLF-100 is a synthetic form of human vasoactive intestinal peptide (VIP), which minimises inflammation in the lungs and protects the alveolar type II cells that are considered to

In May, Gilead Sciences secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its remdesivir to treat of hospitalised Covid-19 patients. Remdesivir is

Following the approval from the drug regulator, Glenmark Pharmaceuticals has launched the generic version of oral antiviral drug Favipiravir under the brand name of FabiFlu. Favipiravir was developed

In Neuville sur Saône in eastern France, Sanofi will build its Evolutive Vaccine Facility (EVF) with an investment of €490m over a five-year period. The vaccine production site

The approval of Zepzelca is for treating metastatic small cell lung cancer in adults whose disease has progressed on or after platinum-based chemotherapy. The alkylating drug, which is

The phase 3 randomised, double-blind and placebo-controlled study will assess the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licenced from Incyte, in hospitalised adults with Covid-19.

Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH